SCHEMBL6095326

SCHEMBL6095326

N#Cc1ccc(OC[C@@H](O)CN2CC3CN(C(=O)NCC4CC4)CC3C2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
KCNH2 Q12809 1/20 0.49
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.43
CHRNA7 P36544 1/20 0.41
MAPK1 P28482 2/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
AGER Q15109 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733792 0.92 MEN1 (0.47) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL6742210 0.92 MEN1 (0.47) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL6743065 0.92 MEN1 (0.47) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL6093806 0.89 CHRNA7 (0.41) MEN1KMT2AKCNH2CHRNA7GRIN1
SCHEMBL6096564 0.89 KCNH2 (0.52) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL5965582 0.88 MEN1 (0.44) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL6733478 0.86 KCNH2 (0.44) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL6097681 0.85 KCNH2 (0.51) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL6095860 0.84 KCNH2 (0.55) MEN1KMT2AKCNH2KDM4EALDH1A1
SCHEMBL6094006 0.84 HRH2 (0.49) CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144914-B2 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2006-12-05 US disclosed
EP-1360187-B1 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053986-A1 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias KCNH1, KCNH2, CACNA1E MEN1 2521/4885KMT2A 3620/4885KCNH2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.